ArQule, Inc. (ARQL) Enrolls First Patient in Phase 1 Trial With ARQ 087, an FGFR Inhibitor  
12/13/2012 10:10:43 AM

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor) activity.